On its first day of trading, Caris Life Sciences enjoyed strong public investor demand for its cancer diagnostics and treatment platform, president David Spetzler tells Axios Pro.
Why it matters: The company decided to go public now following a critical FDA approval for its companion cancer diagnostic last November, alongside reimbursement milestones.
"This is pretty much the earliest we could have [gone public]," Spetzler says.
